<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04445714</url>
  </required_header>
  <id_info>
    <org_study_id>D1683C00013</org_study_id>
    <nct_id>NCT04445714</nct_id>
  </id_info>
  <brief_title>To Assess the Safety of Fixed Dose Combination of Dapagliflozin and Saxagliptin in Indian Type 2 Diabetes Mellitus.</brief_title>
  <official_title>A Prospective, Multicenter, Phase -IV Study to Assess the Safety of Fixed Dose Combination of Dapagliflozin and Saxagliptin in Indian Type 2 Diabetes Mellitus.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, multicenter, phase -IV study to assess the safety of fixed dose combination of
      dapagliflozin and saxagliptin in Indian Type 2 Diabetes Mellitus (T2D) patients.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 30, 2020</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To describe the adverse events profile of dapagliflozin + saxagliptin fixed dose combinations in Indian T2DM patients.</measure>
    <time_frame>24 weeks</time_frame>
    <description>• Adverse Events including Serious adverse events , AEs leading to discontinuation and adverse events of special interest will be checked</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>dapagliflozin and saxagliptin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Singe arm once daily fixed dose combination of Dapa/Saxa 10 mg/5 mg administered orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dapagliflozin and saxagliptin</intervention_name>
    <description>Combination of dapagliflozin and saxagliptin tablet once daily fixed dose combination of Dapa/Saxa 10 mg/5 mg administered orally</description>
    <arm_group_label>dapagliflozin and saxagliptin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provision of signed and dated, written informed consent prior to any study specific
             procedures according to local Indian procedure.

          2. Male and female patients aged &gt; 18 and above

          3. Documented history of type 2 diabetes mellitus with HbA1c level &gt;7.0% and ≤ 10% at
             screening visit

          4. Patients who are on a stable dose of antidiabetic drugs in the past 3 months (includes
             treatment naïve)

          5. Female subjects must be 1 year post-menopausal, surgically sterile, or using an
             acceptable method of contraception

        Exclusion Criteria:

          1. Known allergies or contraindication to the contents of the IP, dapagliflozin or
             saxagliptin tablets.

          2. Active participation in another clinical study with IP and/or investigational device

          3. For women only - currently pregnant (confirmed with positive pregnancy test) or
             breast-feeding.

          4. Type 1 diabetes mellitus.

          5. Patients who have received any SGLT-2 inhibitor or DPP-4 inhibitor or GLP-1 RA in the
             past including in a clinical trial setting.

          6. Patients with moderate to severe renal impairment (eGFR persistently &lt;45 mL/min/1.73
             m2 by CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) formula or end-stage
             renal disease (ESRD) or 'Unstable or rapidly progressing renal disease

          7. Patients with severe hepatic impairment (Child-Pugh class C)

          8. Acute and chronic pancreatitis

          9. Patients with a history of any malignancy

         10. Patients with any of the following CV/Vascular Diseases within 3 months prior to
             signing the consent at enrolment, as assessed by the investigator:

               -  Myocardial infarction.

               -  Cardiac surgery or revascularization (CABG/PTCA).

               -  Unstable angina.

               -  Heart failure (HF)

               -  Transient ischemic attack (TIA) or significant cerebrovascular disease.

               -  Unstable or previously undiagnosed arrhythmia.

         11. Diabetic ketoacidosis

         12. Acute infections
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 4, 2020</study_first_submitted>
  <study_first_submitted_qc>June 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2020</study_first_posted>
  <last_update_submitted>June 22, 2020</last_update_submitted>
  <last_update_submitted_qc>June 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol</mesh_term>
    <mesh_term>Saxagliptin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_time_frame>
    <ipd_access_criteria>When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.`</ipd_access_criteria>
    <ipd_url>https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

